Windward Bio raised $200M in a Series A funding round led by OrbiMed Novo Holdings and Blue Owl Healthcare Opportunities to develop a phase 2-ready monoclonal antibody for asthma and COPD.
Pivotal bioVenture PartnersOrbiMed Novo HoldingsSR OneQuan CapitalBlue Owl Healthcare Opportunities
Description
Windward Bio officially launched with $200 million in Series A financing. The funding will support the development of its lead program, a long-acting anti-TSLP monoclonal antibody, and additional discovery pipeline for bispecifics.
Who to call at Windward Bio, and when
A new round usually means Windward Bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Windward Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Windward Bio, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Windward Bio
Location
Basel, Basel City, Switzerland
About
Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases with an initial focus on severe respiratory conditions. The company is led by a highly experienced team of biopharmaceutical executives with deep discovery, development, and commercialization expertise. The company is advancing a potential best-in-class thymic stromal lymphopoietin (TSLP) monoclonal antibody into phase 2 development and creating novel, long-acting bispecific programs for immunological diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Windward Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BaselBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma